Вопросы современной педиатрии (Jul 2012)

GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS

  • R. V. Denisova,
  • E. I. Alexeeva

DOI
https://doi.org/10.15690/vsp.v11i4.354
Journal volume & issue
Vol. 11, no. 4
pp. 14 – 20

Abstract

Read online

The article represents the results of efficacy and safety evaluation of the human monoclonal antibodies — golimumab, according to the data of international multicenter randomized double-blind placebo-controlled trials, including patients with active stage of rheumatoid arthritis. It was shown, that golimumab was reliably more effective than placebo both when administered hypodermic and intravenous. The safety profile of golimumab is comparable to that of the other tumor necrosis factor alpha blockers. The review also contains information on the 3d phase of golimumab efficacy and safety research in patients with juvenile idiopathic arthritis.

Keywords